FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer
 |
|
BREAKING NEWS
|
| FDA OKs Retifanlimab Combo in Recurrent/Metastatic Anal Cancer Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal. |
|